Agreement involves high content screening (HCS) technology and specific HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation
Cellomics and Evotec Technologies have entered into a worldwide, non-exclusive patent licence agreement.
The agreement will provide Evotec Technologies with Cellomics's core high content screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation.
This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.
Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics's and Evotec Technologies's products as seamless solutions.
This offering will enable cell biologists to obtain the highest quality, most productive results in their drug discovery, systems biology and high content screening efforts.
"We are excited to extend the application portfolio of our Opera platform through this partnership with Cellomics," said Guenter Bauer, chief business officer at Evotec Technologies .
"The combination of highest quality cell assays and highest quality automation will provide important and completely new insight into the biomolecular network of cells.
"Industrialised experimental strategies replace large singular efforts in the new field of systems biology and will ultimately lead to the development of new therapies for diseases".
The two companies will improve the compatibility and integration of their software and assay products, including validation of Cellomics's assay kits by Evotec Technologies.
Additional efforts will bring two-way data flow between the complementary platforms and access to enterprise-wide data storage, management, and analysis.
Daniel Calvo, president of Cellomics, added: "We are very pleased to partner with Evotec Technologies to expand the use of Cellomics technologies across a broader range of applications and throughput protocols.
"The Opera instrument is very complementary with our ArrayScan HCS Reader platform.
"This cooperative development will enable more productive adoption of HCS by our customers, from assay development to screening to Adme/Tox".
